How much revenue does Shanghai Allist Pharmaceuticals make?

Shanghai Allist Pharmaceuticals reported 3.56 billion CNY in revenue for fiscal year 2024, up 76.3% from 2.02 billion CNY in fiscal year 2023. In Q2 2025 revenue was 1.28 billion CNY.

Where does Shanghai Allist Pharmaceuticals make most of its revenue?

China: 99% of revenue by region in fiscal year 2025, followed by Overseas (1%).

What companies are similar to Shanghai Allist Pharmaceuticals?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Jiangsu Hengrui Medicine Co., Ltd. (600276.SS), Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SS), Junshi BIO (688180.SS), Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SS).

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS) Stock

About Shanghai Allist Pharmaceuticals Co., Ltd.

Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl ci...

At a glance

Shanghai Allist Pharmaceuticals reported revenue of 3.56 billion CNY for fiscal year 2024, up 76.3% from fiscal year 2023, and net income of 1.43 billion CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 1.28 billion CNY, up 53.0% from a year before. China was its largest region in fiscal year 2025, with 99% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.